- Lack of energy
- Loss of libido
- Depression
- Loss of muscle mass
AndroGel 1.62% May Lead to Heart Attack and Stroke
When witnessing a product being advertised on television, most understand that the company backing the product is dramatizing situation for their manufactured goods to sell. This understanding does not fall short of pharmaceutical manufacturers and in actuality, is probably the most embellished form of produced mass goods yet. Although advertised as being the solution to a health issue, most of the companies point out the benefits and rush through the risks, saturating the market with positive claims to support their merchandise. This issue has been highlighted by the rampant advertising of testosterone products when no one has proved its worth or the expected risks.
By 2011, 1 in 25 men in their 60s took testosterone. AbbVie, a subsidiary of Abbott Laboratories, spent $80 million in 2012 on aggressive marketing campaigns featuring older men or retired athletes that strive to show how beneficial the product has been in their lives. Their product AndroGel 1.62% has generated over $1 billion in sales that year alone and has since become the top-selling product in the United States. In 2013, the gel grossed about $1.4 billion and commanded about 60% of the testosterone replacement therapy (TRT) market. The combination of effective marketing and ignorance of doctors have allowed for TRT to be readily available to anyone showing signs of low-T. Instead of taking a blood test to get the correct information for hypogonadism (low-T), the symptoms that provide reasoning for taking products such as AndroGel 1.62% include: